Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer

Journal of Clinical Oncology

Volumn 31, Issue 6, 2013, Pages 731-737

  Kim, Hye Ryun ^a,c   Kim, Dae Joon ^b   Kang, Dae Ryong ^b   Lee, Jin Gu ^b   Lim, Sun Min ^b   Lee, Chang Young ^b   Rha, Sun Young ^b   Bae, Mi Kyung ^b   Lee, Young Joo ^b   Kim, Se Hoon ^a   Ha, Sang Jun ^a   Soo, Ross Andrew ^d   Chung, Kyung Young ^a   Kim, Joo Hang ^a   Lee, Ji Hyun ^a   Shim, Hyo Sup ^a   Cho, Byoung Chul ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c National Cancer Center   (South Korea)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVAL; DEATH; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; HUMAN; HUMAN TISSUE; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; SMOKING;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; SMOKING;

EID: 84874888512     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.8622     Document Type: Article

References (29)

1. Turner NC, Seckl MJ: A therapeutic target for smoking-associated lung cancer. Sci Transl Med 2:62ps56, 2010
2. Lee YJ, Kim JH, Kim SK, et al: Lung cancer in never smokers: Change of a mindset in the molecular era. Lung Cancer 72:9-15, 2011
3. Paez JG, Ja?nne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004 (Pubitemid 38720929)
4. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
5. Kim HR, Shim HS, Chung JH, et al: Distinct clinical features and outcomes in never-smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement. Cancer 118:729-739, 2012
6. Soda M, Choi YL, Enomoto M, et al: Identification of the transforming EML4-ALK fusion gene in non-smallcell lung cancer. Nature 448:561-566, 2007 (Pubitemid 47206930)
7. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
8. Perez-Moreno P, Brambilla E, Thomas R, et al: Squamous cell carcinoma of the lung: Molecular subtypes and therapeutic opportunities. Clin Cancer Res 18:2443-2451, 2012
9. Colby TV, Tazelaar HD, Travis WD, et al: Pathologic review of the Mayo Lung Project cancers [corrected]: Is there a case for misdiagnosis or overdiagnosis of lung carcinoma in the screened group? Cancer 95:2361-2365, 2002 (Pubitemid 35351143)
10. Pardo OE, Wellbrock C, Khanzada UK, et al: FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. EMBO J 25:3078-3088, 2006 (Pubitemid 44106760)
11. Dutt A, Ramos AH, Hammerman PS, et al: Inhibitor-sensitive FGFR1 amplification in human nonsmall cell lung cancer. PLoS One 6:e20351, 2011
12. Brooks AN, Kilgour E, Smith PD: Molecular pathways: Fibroblast growth factor signaling - A new therapeutic opportunity in cancer. Clin Cancer Res 18:1855-1862, 2012
13. Freier K, Schwaenen C, Sticht C, et al: Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC). Oral Oncol 43:60-66, 2007 (Pubitemid 46162249)
14. Reis-Filho JS, Simpson PT, Turner NC, et al: FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12:6652- 6662, 2006 (Pubitemid 44876833)
15. Marek L, Ware KE, Fritzsche A, et al: Fibroblast growth factor (FGF) and FGF receptormediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol 75:196-207, 2009
16. Weiss J, Sos ML, Seidel D, et al: Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2:62ra93, 2010
17. Turner N, Pearson A, Sharpe R, et al: FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085-2094, 2010
18. Turner N, Grose R: Fibroblast growth factor signalling: From development to cancer. Nat Rev Cancer 10:116-129, 2010
19. Sasaki H, Shitara M, Yokota K, et al: Increased FGFR1 copy number in lung squamous cell carcinomas. Mol Med Report 5:725-728, 2012
20. Ueba T, Takahashi JA, Fukumoto M, et al: Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues. Neurosurgery 34:221-225, 1994; discussion 225-226
21. Fischer H, Taylor N, Allerstorfer S, et al: Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: Therapeutic implications and synergism with epidermal growth factor receptor inhibition. Mol Cancer Ther 7:3408-3419, 2008
22. Couraud S, Zalcman G, Milleron B, et al: Lung cancer in never smokers: A review. Eur J Cancer 48:1299-1311, 2012
23. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al: Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807, 2003 (Pubitemid 46606235)
24. Wilbertz T, Wagner P, Petersen K, et al: SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Mod Pathol 24:944-953, 2011
25. Lee YJ, Cho BC, Jee SH, et al: Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. J Clin Oncol 28:487-492, 2010
26. Ahrendt SA, Decker PA, Alawi EA, et al: Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92: 1525-1530, 2001 (Pubitemid 32947838)
27. Kakegawa S, Shimizu K, Sugano M, et al: Clinicopathological features of lung adenocarcinoma with KRAS mutations. Cancer 117:4257-4266, 2011
28. Winton T, Livingston R, Johnson D, et al: Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352:2589- 2597, 2005 (Pubitemid 41007845)
29. Pepe C, Hasan B, Winton TL, et al: Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol 25:1553-1561, 2007 (Pubitemid 46733082)